• Sean Maduck, President, Corcept Endocrinology, reported option exercises and share sales in Corcept Therapeutics.
• Exercised options for 25,000 shares at USD 8.27 on Oct. 1-2, 2026.
• Sold 25,000 shares at weighted average prices of USD 115.5373 to USD 116.5534 on Oct. 1-2, 2026.
• Directly held 9,938 shares following the transactions.
• Directly held 41,986 stock options following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-414674), on October 05, 2026, and is solely responsible for the information contained therein.